Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Each stock option granted on June 3, 2025 has an exercise price per share equal to $30.91, Vera's closing trading price on June 3, 2025. Each stock option will vest over four years, with 25% of the underlying shares vesting on the first anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employee's continued service relationship with Vera through the applicable vesting dates. Each of the RSU awards will vest over four years, with 25% of the underlying shares vesting on each anniversary of August 20, 2025, subject to the new employee's continued service relationship with Vera through the applicable vesting dates. The awards are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.
About VeraVera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera's mission is to advance treatments that target the source of immunological diseases in order to change the standard of care for patients. Vera's lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including immunoglobulin A nephropathy (IgAN), also known as Berger's disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. Vera also holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B cell mediated diseases. For more information, please visit www.veratx.com.
For more information, please contact:
Investor Contact:Joyce AllaireLifeSci Advisors212-915-2569jallaire@lifesciadvisors.com
Media Contact:Debra CharlesworthVera Therapeutics415-854-8051corporatecommunications@veratx.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
HCM III Acquisition Corp. Announces Pricing of $220 Million Initial Public Offering
STAMFORD, CT, July 31, 2025 (GLOBE NEWSWIRE) -- HCM III Acquisition Corp. (the 'Company'), a blank check company whose business purpose is to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, announced today that it has priced its initial public offering of 22,000,000 units at $10.00 per unit. Each unit consists of one Class A ordinary share and one-third of one redeemable warrant. The units will be listed on the Nasdaq Global Market ('Nasdaq') and will begin trading tomorrow, August, 1, 2025, under the ticker symbol 'HCMAU." Each whole warrant is exercisable to purchase one Class A ordinary share of the Company at a price of $11.50 per share. Only whole warrants are exercisable and will trade. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on the Nasdaq under the symbols 'HCMA' and 'HCMAW,' respectively. Cantor Fitzgerald & Co. is acting as sole bookrunner for the offering. The Company has granted the underwriters a 45-day option to purchase up to an additional 3,300,000 units at the initial public offering price to cover over-allotments, if any. The Company intends to focus on identifying businesses which provide disruptive technology or innovations within the financial services industry. The Company's efforts will be focused on acquiring established businesses that it believes are fundamentally sound, but in need of assistance to maximize their potential value. The Company is led by Shawn Matthews, Chairman and Chief Executive Officer; and Steve Bischoff, Chief Financial Officer. The public offering is being made only by means of a prospectus. When available, copies of the prospectus relating to the offering may be obtained from: Cantor Fitzgerald & Co., Attention Capital Markets, 499 Park Avenue, New York, NY 10022, or by e-mail at prospectus@ A registration statement relating to the securities was filed with, and declared effective by, the Securities and Exchange Commission ('SEC') on July 31, 2025. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. FORWARD-LOOKING STATEMENTS This press release contains statements that constitute 'forward-looking statements.' Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the 'Risk Factors' section of the Company's registration statement filed with the SEC and the preliminary prospectus included therein. Copies of these documents are available on the SEC's website, The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. About HCM III Acquisition Corp. HCM III Acquisition Corp. is a newly organized blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The Company intends to focus on identifying businesses which provide disruptive technology or innovations within the financial services industry. The Company's efforts will be focused on acquiring established businesses that it believes are fundamentally sound, but in need of assistance to maximize their potential value. Media Contact:Steve Bischoff sbischoff@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
MicroStrategy earnings beats expectations by over 35,000%
MicroStrategy earnings beats expectations by over 35,000% originally appeared on TheStreet. MicroStrategy (NASDAQ: MSTR) posted outstanding quarterly earnings of $32.52 per share, above the average expectation of -$0.09 by 35,447.83%. This is a 4,378.95% improvement over the -$0.76 per share loss posted in the same period previous year. The firm also reported sales of $114.49 million, which was slightly more than the projected $112.96 million and above projections by 1.35%. Sales increased 2.73% from $111.44 million in the same quarter a year earlier. Strategy, previously known as MicroStrategy, is the world's first and largest Bitcoin Treasury Company. These results come on the heels of Strategy increasing its preferred 'Stretch' stock offering to fund $2.47 billion to cover additional Bitcoin purchases. Previous quarter EPS losses Strategy's financial performance has been far from steady over the past ten years; its recent trajectory was primarily due to its aggressive buying of Bitcoin. MicroStrategy's profits have been somewhat volatile, primarily and likely due to the company's significant investment in corporation reported a substantial loss in the first quarter of 2025, amounting to -$16.49 per share, which was far worse than the expected -$2.44. This was a 575% negative earnings surprise. This happened following a string of growing losses in 2024. Earnings Per Share (EPS) for the fourth quarter was -$3.03, representing a 3,214% surprise compared to the prediction of -$0.09. EPS for the third quarter was -$1.72, a 1,298% surprise compared to the predicted -$0.12. This trend follows a longer-term pattern: MicroStrategy made steady but small profits from 2010 to 2019, but its recent turn to Bitcoin has amplified its earnings fluctuations. The habit of underperformance began in the first quarter of 2024, when EPS missed its expectation of -$0.05 by -$0.31. The second quarter of 2023, on the other hand, had a +900% surprise, with EPS of $0.15 instead of the expected -$0.02. These significant changes indicate that MicroStrategy's finances remain highly sensitive to fluctuations in the crypto market, as pointed by analysts, making it challenging for traditional investors to estimate earnings and understand the company's financials. The company is also going to discuss its second quarter results in a webinar at 5PM ET. MicroStrategy earnings beats expectations by over 35,000% first appeared on TheStreet on Jul 31, 2025 This story was originally reported by TheStreet on Jul 31, 2025, where it first appeared.
Hamilton Spectator
an hour ago
- Hamilton Spectator
Perseus Mining announces retirement of CEO and appointment of new CEO
Perth, Aug. 01, 2025 (GLOBE NEWSWIRE) — perseus mining MANAGING DIRECTOR announces retirement; new MD & CEO appointed SUMMARY Perseus Mining Limited (ASX/TSX:PRU) announces its long-serving Managing Director and Chief Executive Officer (MD and CEO) Jeff Quartermaine has advised he will retire from the role of Perseus's MD and CEO after serving for 12 years. His retirement will take effect from September 30, 2025, after which he has agreed to continue to support the Company through a Consultancy Agreement on market terms. Mr. Quartermaine joined Perseus in 2010 as Chief Financial Officer, before being appointed CEO in 2013. Since assuming this role, he has transformed Perseus from a struggling single-mine, single-country company to a multi-mine, multi-jurisdictional gold producer, developer and explorer that has consistently delivered on its promises and is now one of the leading gold companies operating on the African continent. Perseus now has three operating gold mines, Edikan in Ghana and Yaouré and Sissingué in Côte d'Ivoire, and is building a fourth mine, Nyanzaga, in Tanzania, which is on track to commence gold production in Q1 CY2027. Perseus's Chairman Rick Menell praised Mr Quartermaine's outstanding contribution in leading and shaping Perseus into the company it is today, saying: ' On behalf of the Board, I would like to express my most sincere gratitude to Jeff for his leadership and guidance over the years. Jeff has transformed Perseus and has been pivotal in turning it into one of the most profitable gold producers in the world. He has built extremely solid foundations for the Company to keep growing and we cannot thank him enough for such a positive legacy .' Outgoing MD and CEO, Mr. Quartermaine said: 'It has been an honour and a privilege to have had the opportunity to serve at the helm of Perseus Mining over the past 12 years. Not only has the Company been transformed into a credible ASX 100 organisation, but during this time we have generated significant benefits for all of our stakeholders, including many in our host communities in Africa whose lives have been significantly improved through Perseus's endeavours. I am deeply indebted to all our staff, both past and present, who along with their families have given their friendship, hard work, and commitment in helping transform Perseus. Along the way we have faced a myriad of challenges including events such as the global COVID pandemic, but we have emerged stronger than ever, and the company is now well positioned to continue our success into the future. In reflecting on the last 15 years at Perseus, I must acknowledge the enormous contribution made to my career and indirectly to the success of Perseus, by my own family whose unwavering support has made the journey so much easier.' Mr. Quartermaine will be replaced as MD and CEO by Craig Jones, who will commence work with Perseus on August 18, 2025 and will assume the positions of MD and CEO with effect from October 1, 2025. Mr Jones joins Perseus with more than 25 years of global experience, having worked across Australia, Papua New Guinea (PNG), Indonesia and Canada. He was a member of Newcrest's executive team from 2012, having originally joined in 2008, and ultimately serving as Newcrest's global COO, with broad responsibility for five operating assets spread across multiple jurisdictions. In that capacity, he played a critical role in the development of organisational strategies, due diligence and investor relations. Mr Jones also led high-level engagement with governments, communities and First Nations groups across PNG, Canada and Australia. Beyond his executive roles, Mr. Jones was a Newcrest nominee director on the Boards of SolGold and Lundin Gold and was Newcrest's representative on Joint Venture Committees including the Morobe Mining Joint Venture in PNG and the Red Chris Joint Venture in British Columbia, reflecting extensive global resource-sector connectivity and governance experience. A values-driven leader recognised for enhancing safety and fostering a strong organisational culture, Mr Jones is known for his consistent, empathetic and principled leadership style, which has earned the respect of peers, governments and communities alike. Mr Menell said: 'We are delighted to welcome Craig to the Perseus team as Managing Director and CEO. Perseus is going through a significant phase of growth, in an environment that is getting increasingly complex, so we need a leader of Craig's calibre to build on Jeff's incredible legacy and confirm – and further grow – our position as one of the world's better performing mid-tier gold producers. Craig brings a wealth of strategic, operational and technical expertise, a deep understanding of complex operating jurisdictions and stakeholder management and a clear commitment to sustainable practices. We look forward to working with Craig and the rest of the Perseus team to bring the Company even further.' Mr. Jones will be based in Perseus's head office in Perth, Western Australia. A summary of the material terms of the employment agreement between Perseus and Mr. Jones is provided in Appendix A of this announcement. Appendix A: CEO Summary of Key Terms of employment This market announcement was authorised for release by the Chairman of the Board of Perseus Mining Limited, Rick Menell.
